Direct oral anticoagulant drugs (DOACs) are available in addition to warfarin for the
treatment of patients with non‐valvular atrial fibrillation (NVAF). Anticoagulants are useful for …

Direct oral anticoagulants (DOACs) have increasingly replaced warfarin for treating patients
with non‐valvular atrial fibrillation (NVAF). DOACs have been demonstrated to be more …

Purpose To compare the effectiveness and safety of reduced or standard daily doses of
direct oral anticoagulants (DOACs) with warfarin in Japanese patients with nonvalvular atrial …

The present study aimed to assess the associations between dosing of DOACs and
outcomes in patients with non-valvular atrial fibrillation (NVAF). Direct oral anticoagulants …

Background Direct oral anticoagulants (DOACs) have a better risk benefit profile in Asian
patients with atrial fibrillation (AF). Whether treatment effects could be modified by drug class …

Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin in
Asian patients with nonvalvular atrial fibrillation (NVAF) remains unclear. Methods This …

Background Two forms of direct oral anticoagulant (DOAC) have recently been introduced:
direct thrombin inhibitors (DTI; eg, dabigatran) and factor Xa inhibitors (FXa; eg, rivaroxaban …

In the pivotal randomized controlled trials (RCTs) for patients with atrial fibrillation, direct oral
anticoagulants (DOACs) had similar or even superior efficacy and safety compared with …

Objectives To examine the incidence of stroke or systemic embolic events (SSEs) and
bleeding events in untreated patients with non-valvular atrial fibrillation (NVAF) after …

Aims There are conflicting signals in the literature about comparative safety and
effectiveness of direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) …